Subsequently, the results obtained from the PALOMA-3 trial led to the approval for the use of palbociclib together with fulvestrant in ER-positive and HER2-negative BC patients sensitive to endocrine therapy [99]. This evidence concerns the gene ESR1 and breast cancer.